Physician profile
Mahnoor Moin
NPI 1639686009
$3,434.21
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $675 · 2022: $1,214 · 2023: $861 · 2024: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.97 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $627.61 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.43 | 2021-2023 | Xifaxan |
| Celgene Corporation | $207.36 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $164.86 | 2022-2024 | Vemlidy |
| Janssen Biotech, INC. | $152.26 | 2021-2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $124.45 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $123.84 | 2021 | |
| Enterra Medical, INC. | $117.64 | 2024 | |
| Mallinckrodt Hospital Products INC. | $107.75 | 2023 | Terlivaz |
| Pfizer INC. | $95.08 | 2021-2022 | |
| Ardelyx, INC. | $79.96 | 2022-2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $55.06 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $53.48 | 2023 | Stelara |
| Qol Medical, LLC | $33.46 | 2023 | Sucraid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $30.34 | 2023 | Suflave |
| Redhill Biopharma INC. | $19.59 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.43 | 2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $13.64 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahnoor Moin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.